

Filgotinib Marks Expansion into Inflammation with Potential for 5 Launches in Next 4 Years

Inflammation

Filgotinib

Selective JAK-1 inhibitor with **potential best-in-class profile**


Strong efficacy for remission and demonstrated safety
at both doses; favorable benefit/risk profile at high dose

Submitted for RA in U.S., Europe and Japan

P3 UC data in H1 2020



COVID-19 Insight: Filgotinib for RA filed with regulators globally, including U.S., Europe and Japan. We are continuing to prepare for launch and are in close contact with regulators to understand the effect that COVID-19 could have on review timelines. At this time we do not expect the Filgotinib SELECTION-1 study in UC to be adversely impacted.



Preparing for competitive RA launch with highly experienced team



Building a Broad Inflammation and Fibrosis Portfolio with Galapagos Beyond Filgotinib


Inflammation




Doubles Gilead's R&D footprint and accelerates transformational therapy development

9 clinical programs^{1,2}

>20 pre-clinical programs²



Selected programs



Lighter shade - new or progressed to next phase since Q4'19

¹ Excluding filgotinib. ² Optionable partner programs, except for GLPG-1690 which is an optioned partner program. ³ Autotaxin inhibitor. ⁴ GPR84 antagonist. ⁵ Toledo - dual mechanism anti-inflammatory. IPF - Idiopathic Pulmonary Fibrosis. OA - Osteoarthritis. Selected pre-clinical and P1 assets displayed.



Anticipated Milestones Through 2021



COVID-19 Insight: Most clinical trial enrollment will be slowed or halted due to site and participant availability during pandemic, which may result in delays in anticipated milestones. We will continue to monitor the situation and expect to provide additional insights and updates during our Q2'20 earnings call.

Filgotinib
P3 UC data

GLPG-1972¹
P2 OA data

Filgotinib
Expected RA approvals in U.S., Europe, Japan

Filgotinib
MANTA/MANTA-RAy enrollment completion

GLPG-1690²
P3 IPF fertility analysis data

Filgotinib (moved from H2'20)
P3 enrollment completion for CD

H1 2020

H2 2020

2021



Inflammatory Disease Pipeline

		Pre-Clinical	Phase 1	Phase 2	Phase 3	NDA/BLA/MAA	Updates since Q4'19	
Inflammatory Disease	Filgotinib JAK-1 inhibitor (GS-6034)	Rheumatoid arthritis	[Progressed to NDA/BLA/MAA]					
	Filgotinib JAK-1 inhibitor (GS-6034)	Ulcerative colitis	[Progressed to Phase 3]					
	Filgotinib JAK-1 inhibitor (GS-6034)	Crohn's disease	[Progressed to Phase 3]					
	Filgotinib JAK-1 inhibitor (GS-6034)	Psoriatic arthritis	[Progressed to Phase 3]					
	Filgotinib JAK-1 inhibitor (GS-6034)	Ankylosing spondylitis	[Progressed to Phase 2]					
	Filgotinib JAK-1 inhibitor (GS-6034)	Uveitis	[Progressed to Phase 2]					
	TPL2 inhibitor (GS-4875)	Ulcerative colitis	[Progressed to Phase 2]					
	GLPG-1972 ¹	Osteoarthritis	[Progressed to Phase 2]					
	GLPG-0555 ¹	Inflammatory diseases	[Progressed to Phase 1]					
	GLPG-3312 ¹	Inflammatory diseases	[Progressed to Phase 1]					
	GLPG-3970 ¹	Inflammatory diseases	[Progressed to Phase 1]					
	GLPG-3667 ¹	Inflammatory diseases	[Progressed to Phase 1]					
	GLPG-3121 ¹	Inflammatory diseases	[Progressed to Phase 1]					NEW
	IRAK4 inhibitor (GS-5718)	Inflammatory diseases	[Progressed to Pre-Clinical]					
	α4β7 inhibitor (GS-1427)	Inflammatory diseases	[Progressed to Pre-Clinical]					
	Small molecule inh. (Neutrophil target)	Inflammatory diseases	[Progressed to Pre-Clinical]					
	Small molecule inh. (Innate immunity target)	Inflammatory diseases	[Progressed to Pre-Clinical]					
	GLPG-4399 ¹	Inflammatory diseases	[Progressed to Pre-Clinical]					
	GLPG-4259 ¹	Inflammatory diseases	[Progressed to Pre-Clinical]					
	GLPG-4471 ¹	Inflammatory diseases	[Progressed to Pre-Clinical]					
GLPG-4059 ¹	Metabolic diseases	[Progressed to Pre-Clinical]						
Fibrotic Disease	Cilofexor FXR agonist (GS-9674)	PSC	[Progressed to Phase 3]					
	GLPG-1690 ²	IPF	[Progressed to Phase 3]					
	Cilofexor, firsocostat, selonsertib combination ³	NASH	[Progressed to Phase 2]					
	Selonsertib ASK1 inhibitor (GS-4997)	DKD	[Progressed to Phase 2]					
	GLPG-1690 ²	Systemic sclerosis	[Progressed to Phase 2]					
	GLPG-1205 ¹	IPF	[Progressed to Phase 2]					
	GLPG-4124 ¹	Fibrosis	[Progressed to Pre-Clinical]					

Lighter shade - new or progressed to next phase since Q4'19

¹ Optionable partner program. ² Optioned partner program. ³ Cilofexor FXR agonist, firsocostat ACC inh., selonsertib ASK1 inh. Combination. IPF - Idiopathic pulmonary fibrosis. Selected pre-clinical assets displayed.

